A Study of miRNA 371 in Patients with Germ Cell Tumors

This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.

Disease Sites:

Urologic

Staging:

N/A

Age Group:

Adults

Therapies:

Not Available

Drugs:

Not Available

Principal Investigator(s):

Rini, Brian

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

10-09-2020

Trial Type:

Basic Science

Protocol ID:

SWOGUROS1823

National Clinical Trial ID:

NCT04435756

View Internal Documents

Eligibility

Ages Eligible for Study:

18 Years

Genders Eligible for Study:

BOTH

Accepts Healthy Volunteers?:

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Study of miRNA 371 in Patients with Germ Cell Tumors

Eligibility